ATP2B3

Across TCGA pan-cancer cohorts, ATP2B3 mass-spec protein differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of ATP2B3’s most consistent transcriptional readouts.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where ATP2B3 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types ATP2B3 is over-expressed in tumor, although a few such as PDAC and CCRCC show the opposite, repressed pattern.

PDAC and CCRCC are the cancer types where ATP2B3 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ATP2B3 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
PDAC	All	All	−2.550	.029	2	view →
CCRCC	Male	III,IV	−0.755	.032	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 2 strongest of 2 lineages.

ATP2B3–PDAC

Open the PDAC breakdown →